Literature DB >> 24756193

Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.

Loredana La Mantia1, Valentina Prone, Maria Raffaella Marazzi, Cristina Erminio, Alessandra Protti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24756193     DOI： 10.1007/s10072-014-1800-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  9 in total

1.  Rebound of disease activity during pregnancy after withdrawal of fingolimod.

Authors:  A P Sempere; L Berenguer-Ruiz; E Feliu-Rey
Journal:  Eur J Neurol       Date:  2013-08       Impact factor: 6.089

2.  Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.

Authors:  David Henault; Lorna Galleguillos; Craig Moore; Trina Johnson; Amit Bar-Or; Jack Antel
Journal:  Neurology       Date:  2013-10-16       Impact factor: 9.910

3.  Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.

Authors:  A Ghezzi; M A Rocca; D Baroncini; P Annovazzi; M Zaffaroni; G Minonzio; G Comi; M Filippi
Journal:  J Neurol       Date:  2012-11-16       Impact factor: 4.849

4.  Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.

Authors:  Claus Michael Gross; Annette Baumgartner; Sebastian Rauer; Oliver Stich
Journal:  Neurology       Date:  2012-10-03       Impact factor: 9.910

5.  Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.

Authors:  Masami Tanaka; Kwiyoung Park; Keiko Tanaka
Journal:  Mult Scler       Date:  2013-01-15       Impact factor: 6.312

6.  Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.

Authors:  E Piscolla; B Hakiki; L Pastò; L Razzolini; E Portaccio; M P Amato
Journal:  J Neurol       Date:  2013-05-05       Impact factor: 4.849

7.  Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.

Authors:  Bahia Hakiki; Emilio Portaccio; Marta Giannini; Lorenzo Razzolini; Luisa Pastò; Maria Pia Amato
Journal:  Mult Scler       Date:  2012-07-24       Impact factor: 6.312

Review 8.  Fingolimod therapy for multiple sclerosis.

Authors:  Mary A Willis; Jeffrey A Cohen
Journal:  Semin Neurol       Date:  2013-05-25       Impact factor: 3.420

9.  Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.

Authors:  Joachim B Havla; Hannah L Pellkofer; Ingrid Meinl; Lisa Ann Gerdes; Reinhard Hohlfeld; Tania Kümpfel
Journal:  Arch Neurol       Date:  2012-02
  9 in total
  7 in total

1.  Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.

Authors:  Jonathan Calkwood; Timothy Vollmer; Robert J Fox; Ray Zhang; Mark Novas; Sarah I Sheikh; Vissia Viglietta
Journal:  Int J MS Care       Date:  2016 May-Jun

Review 2.  Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alberto Gajofatto; Marco Turatti; Salvatore Monaco; Maria Donata Benedetti
Journal:  Drug Healthc Patient Saf       Date:  2015-12-11

Review 3.  Neurological safety of fingolimod: An updated review.

Authors:  Fumihito Yoshii; Yusuke Moriya; Tomohide Ohnuki; Masafuchi Ryo; Wakoh Takahashi
Journal:  Clin Exp Neuroimmunol       Date:  2017-06-18

4.  Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.

Authors:  Kazunori Sato; Masaaki Niino; Atsushi Kawashima; Moemi Yamada; Yusei Miyazaki; Toshiyuki Fukazawa
Journal:  Intern Med       Date:  2018-04-27       Impact factor: 1.271

Review 5.  Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.

Authors:  Kerri A Schoedel; Carine Kolly; Anne Gardin; Srikanth Neelakantham; Kasra Shakeri-Nejad
Journal:  Psychopharmacology (Berl)       Date:  2021-11-13       Impact factor: 4.530

6.  Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption.

Authors:  Roberto De Masi; Salvatore Accoto; Stefania Orlando; Vincenzo De Blasi; Sergio Pasca; Rocco Scarpello; Leo Spagnolo; Adele Idolo; Antonella De Donno
Journal:  BMC Neurol       Date:  2015-07-31       Impact factor: 2.474

7.  A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo.

Authors:  Patrick Vermersch; Ernst-Wilhelm Radue; Norman Putzki; Shannon Ritter; Martin Merschhemke; Mark S Freedman
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.